Market Overview

Slingshot Insights' Expert Conference Call On Lipocine

Slingshot Insights' Expert Conference Call On Lipocine

Lipocine Inc (NASDAQ: LPCN)’s LPCN-1021’s PDUFA date is coming up on June 28. Given the major potential near-term catalyst, Slingshot Insights recently conducted an expert conference call with a professor, researcher and a clinical director from the Department of Medicine at Johns Hopkins University on June 9 to allow investors the chance to ask questions about the oral male hypogonadism drug. Here are some highlights from the call.

In terms of market penetration, the expert told callers, “There is a need for an oral medication. I think it’s going to take a big chunk of the market if it gets approved.”

Related Link: Valeant Isn't A Short-Term Fix

The doctor said Americans will prefer the pill to the topical creams that are out there in the market already, but the problem will be price.

“Patients will want the pill, but the problem might be due to the insurance companies, patients who are not going to pay for this expensive pill, when you can get generic gel that’s already on the market,” he said.

The doctor also discussed whether or not the high levels of DHT reported in the trials should be a concern and what the FDA might require from Lipocine if the drug isn’t approved.

Slingshot is now proposing a second conference call with a new set of investor questions about Lipocine. To sign up to participate in the call, click here.

Disclosure: The author holds no position in the stocks mentioned.

Latest Ratings for LPCN

Mar 2018Initiates Coverage OnBuy
Feb 2018UpgradesHoldBuy
Jan 2018DowngradesBuyHold

View More Analyst Ratings for LPCN
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News FDA Events Analyst Ratings Trading Ideas General


Related Articles (LPCN)

View Comments and Join the Discussion!

Latest Ratings

ELMDDougherty & Co.Initiates Coverage On12.0
MRNSCantor FitzgeraldAssumes7.0
MNRLCapital One FinancialInitiates Coverage On23.0
SONVertical GroupUpgrades
UNPMorgan StanleyMaintains136.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Airbnb Fights Harsh Legislation Passed By San Francisco City Government

Argentina Is Awesome: The ETF, Not Lionel Messi